The most powerful and NLRP3-specific of the direct NLRP3 inhibitors is the diaryl sulfonylurea compound MCC950, which showed therapeutic efficacy in several preclinical immunopathological models, such as experimental autoimmune encephalomyelitis (EAE), which is a disease model of MS, and rat models of AD and PD [143,144,145]. This evidence concerns the gene NLRP3 and myeloid sarcoma.